No Data
Afternoon session [Active stocks and traded stocks]
*Bio-Chemicals <4548> 776 +12 A phase 3 clinical trial for osteoarthritis treatment product 'Gel-One' has commenced in Japan. The resistance to further gains is significant. *Riken Technos <4220> 1025 +2625 The upward revision of the financial estimates for the fiscal year ending March 2025 and the announcement of a Share Buyback program of 3.8% of outstanding stocks. *SCSK <9719> 3776 +13 Domestic securities have upgraded their rating due to expected synergy effects from the integration. The resistance to further gains is significant. *GladCube <9561> 1168 -92 The global...
February 25 [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Escrow Agent Japan <6093> 160 yen (2/21) Engaged in real estate-related business such as escrow (third-party deposit), contract services, human resource dispatch, and auctions. While promoting the digital transformation of registration-related operations associated with real estate transactions, obtained a Business model patent for the cloud play in the progress management system, "EAJ Platform System (EPS)," and the business processes utilizing it.
Focus on biochemistry and Star Micronics HD, while V-Cube and high-pressure gas seem to be soft.
In the Tokyo market during the three-day weekend, on the 21st, the Dow Jones Industrial Average fell by $748.63, while yesterday, the 24th, it rose by $33.19 to $43,461.21. The Nasdaq Composite Index dropped by 438.36 points on the 21st and fell by 237.08 points yesterday to 19,286.93. Yesterday, the Chicago Nikkei 225 Futures were down 770 yen from Osaka daytime, at 38,020 yen. The exchange rate is 1 dollar = 149.60-70 yen. In today's Tokyo market, a special profit (subsidy income) of 5.09 is expected for the fourth quarter of the fiscal year ending February 2025.
Biochemistry --- A pharmaceutical company with strengths in "carbohydrate science" has obtained approval for hernia-related Pharmaceuticals from U.S. authorities, which will be a future catalyst.
Bikakukagaku Industry (4548) is a pharmaceutical company that has been established for over 70 years. Specializing in the scientific field of "Carbohydrate Science," which involves complex carbohydrates and sugar chains, the company has produced numerous Pharmaceuticals and Medical Devices. The distinctive feature of their Business model is that they narrow down their research and development targets and diseases, engaging in niche research and development activities that utilize their technology and know-how related to carbohydrate science. Additionally, the company does not have a pharmaceutical sales division and develops a Business model that forms sales partnerships with pharmaceutical companies that have strengths in various product areas.
MITSUBISHI ESTATE, 3Q operating profit increased by 32.5% to 194.4 billion yen.
MITSUBISHI ESTATE <8802> announced its financial results for the third quarter of the fiscal year ending March 2025, with operating revenue increasing by 13.1% year-on-year to 1 trillion 47.9 billion 19 million yen, and operating profit rising by 32.5% to 194.4 billion 78 million yen. Both income and capital gains are progressing smoothly towards the company's full-year financial estimates. In Japan, the stable Market Overview is being leveraged, leading to an increase in capital gains. Additionally, the Brokerage business is performing well. [Positive Evaluation] <8802> MITSUBISHI ESTATE Q4| <7740> TAMRON
Seikagaku: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2025 [Japanese GAAP] (Consolidated)